Annual report
3055.TEDINET S100R67P
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥262.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥239.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥243.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥235.2bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥2.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.7bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.1bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.5bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥4.2bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.8bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.0bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥137.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥136.9bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥133.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥130.7bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥125.1bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥80.5bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥81.3bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥57.4bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥54.4bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥52.7bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥51.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥18.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥18.0bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.6bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥20.9bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥828m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.9bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥835m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥731m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥444m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥530m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥123.41 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.01 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥86.81 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.96 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,614.23 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,460.67 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,346.36 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,239.8 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,170.74 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 41.6% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,626 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 1,625 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 1,570 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 1,485 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 1,441 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥1.9bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥1.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥6.7bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥712m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥174m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥799m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥289m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥785m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥605m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.3bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.2bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥648m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥619m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥637m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥204m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥5.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥44.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥44.5bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥44.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥40.3bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥40.4bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.4bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥42.9bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.9bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥43.1bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥40.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥40.2bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.9bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥52.36 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.27 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.33 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥8.7 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥225.79 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,955.09 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,900.56 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,859.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,701.04 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,709.32 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 96.8% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 99.4% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 99.5% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 2.7% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.4% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.5% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 24,400,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 63 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 62 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 53 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 57 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 89
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥52m |
| Otherother segments | revenue | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| Otherother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥60m |
| Otherother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥2.0bn |
| Otherother segments | segment assets | at 2023-03-31 | ¥44.5bn |
| Otherother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥717m |
| Dispensing Industryreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥88m |
| Dispensing Industryreportable segment | employees | at 2023-03-31 | 331 pure |
| Dispensing Industryreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥13.5bn |
| Dispensing Industryreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥13.5bn |
| Dispensing Industryreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥12m |
| Dispensing Industryreportable segment | segment assets | at 2023-03-31 | ¥6.3bn |
| Dispensing Industryreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥0 |
| Information And Communication Technology Industryreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥21m |
| Information And Communication Technology Industryreportable segment | employees | at 2023-03-31 | 76 pure |
| Information And Communication Technology Industryreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥487m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Information And Communication Technology Industryreportable segment | segment assets | at 2023-03-31 | ¥813m |
| Information And Communication Technology Industryreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥59m |
| Medical Equipment Wholesale Industryreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥229m |
| Medical Equipment Wholesale Industryreportable segment | employees | at 2023-03-31 | 409 pure |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥66.4bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥65.9bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥490m |
| Medical Equipment Wholesale Industryreportable segment | segment assets | at 2023-03-31 | ¥27.8bn |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Nursing Industryreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥171m |
| Nursing Industryreportable segment | employees | at 2023-03-31 | 255 pure |
| Nursing Industryreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥4.1bn |
| Nursing Industryreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥4.1bn |
| Nursing Industryreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥4m |
| Nursing Industryreportable segment | segment assets | at 2023-03-31 | ¥5.5bn |
| Nursing Industryreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥335m |
| Wholesaler Of Drugs Industryreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥520m |
| Wholesaler Of Drugs Industryreportable segment | employees | at 2023-03-31 | 479 pure |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥186.6bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥178.0bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥8.6bn |
| Wholesaler Of Drugs Industryreportable segment | segment assets | at 2023-03-31 | ¥89.7bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥961m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥274.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥262.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥12.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥174.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥3.6bn |
| Otherother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥44m |
| Otherother segments | revenue | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Otherother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥58m |
| Otherother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Otherother segments | segment assets | at 2022-03-31 | ¥44.6bn |
| Otherother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥179m |
| Dispensing Industryreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥93m |
| Dispensing Industryreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥13.7bn |
| Dispensing Industryreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13.7bn |
| Dispensing Industryreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥13m |
| Dispensing Industryreportable segment | segment assets | at 2022-03-31 | ¥6.4bn |
| Dispensing Industryreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥159m |
| Information And Communication Technology Industryreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥19m |
| Information And Communication Technology Industryreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥522m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥961m |
| Information And Communication Technology Industryreportable segment | segment assets | at 2022-03-31 | ¥894m |
| Information And Communication Technology Industryreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥90m |
| Medical Equipment Wholesale Industryreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥256m |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥62.3bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥61.8bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥471m |
| Medical Equipment Wholesale Industryreportable segment | segment assets | at 2022-03-31 | ¥25.2bn |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥1.2bn |
| Nursing Industryreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥173m |
| Nursing Industryreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥3.8bn |
| Nursing Industryreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥3.8bn |
| Nursing Industryreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥10m |
| Nursing Industryreportable segment | segment assets | at 2022-03-31 | ¥4.7bn |
| Nursing Industryreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥348m |
| Wholesaler Of Drugs Industryreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥493m |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥177.2bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥168.5bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥8.7bn |
| Wholesaler Of Drugs Industryreportable segment | segment assets | at 2022-03-31 | ¥91.6bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥582m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥260.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥248.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥173.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥2.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,751
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Note on change of independent auditors audits (text) | CurrentYearDuration | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Name of group company holding largest amount of investment shares in group | CurrentYearInstant | Original text (Japanese)株式会社ほくやく | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | － | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment largest holding company | CurrentYearDuration | Original text (Japanese)取引先持株会を通じた株式の取得 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)エーザイ株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)大塚ホールディングス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)東邦ホールディングス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)（保有目的）業界動向把握のため（定量的な保有効果） （注）１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)キッセイ薬品工業株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)株式会社バイタルケーエスケーホールディングス | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)（保有目的）主として医薬品卸売事業における協業関係維持・強化のため（定量的な保有効果） （注）１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)久光製薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)株式会社北洋銀行 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)株式会社ほくほくフィナンシャルグループ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)中道リース株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)（保有目的）地場企業としての関係強化のため（定量的な保有効果） （注）１ | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)小林製薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row10Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)扶桑薬品工業株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row11Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)わかもと製薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment largest holding company | CurrentYearInstant_Row12Member | Original text (Japanese)有 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |